{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:55:58Z","timestamp":1753887358438,"version":"3.41.2"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"vor","delay-in-days":122,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601183"],"award-info":[{"award-number":["81601183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Evidence-Based Complementary and Alternative Medicine"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2\u20134 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. <jats:italic>Methods<\/jats:italic>. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine\u2010diazepam, or paroxetine\u2010MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self\u2010Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. <jats:italic>Results<\/jats:italic>. Both paroxetine\u2010MSZRT and paroxetine\u2010diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine\u2010MSZRT as well as paroxetine\u2010diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks\u2019 treatment, the overall effectiveness rate in the paroxetine\u2010MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine\u2010diazepam group (93.88%). <jats:italic>Conclusion<\/jats:italic>. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.<\/jats:p>","DOI":"10.1155\/2017\/8391637","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T21:01:14Z","timestamp":1493845274000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study"],"prefix":"10.1155","volume":"2017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-4899","authenticated-orcid":false,"given":"Ming-Fen","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-5604","authenticated-orcid":false,"given":"Lin-Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4138-4237","authenticated-orcid":false,"given":"Wen-Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-742X","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-7496","authenticated-orcid":false,"given":"Xiao-Yun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-3486","authenticated-orcid":false,"given":"Ting-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-9623","authenticated-orcid":false,"given":"Sheng-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-8136","authenticated-orcid":false,"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-9702","authenticated-orcid":false,"given":"Yong-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.31"},{"key":"e_1_2_8_2_2","first-page":"2120","article-title":"Pregabalin versus sertraline in generalized anxiety disorder. An open label study","volume":"19","author":"Cvjetkovic-Bosnjak M.","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2016.00020"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0917-3"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2014.10.005"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-2975-2"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0305-4"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900006945"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710001434"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-016-0668-3"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0113"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.37"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2004.07.043"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/710895"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008459"},{"key":"e_1_2_8_16_2","first-page":"25","article-title":"Efficacy of adepress (paroxetine) in generalized anxiety disorder","volume":"110","author":"Chakhava V. O.","year":"2010","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00189.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.02.009"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.03.040"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.18"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713001475"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2009.01.009"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01643-8"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.49"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/913252"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/15402002.2016.1163703"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mhpa.2015.09.002"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.09.033"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-007-9197-8"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-006-9137-z"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/697893"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4198-1"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.03.045"}],"container-title":["Evidence-Based Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2017\/8391637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2017\/8391637.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2017\/8391637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:23:01Z","timestamp":1722910981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2017\/8391637"}},"subtitle":[],"editor":[{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1155\/2017\/8391637"],"URL":"https:\/\/doi.org\/10.1155\/2017\/8391637","archive":["Portico"],"relation":{},"ISSN":["1741-427X","1741-4288"],"issn-type":[{"type":"print","value":"1741-427X"},{"type":"electronic","value":"1741-4288"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2017-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8391637"}}